Area of research
Genetics · Hematology
Research interest
Research interests include Hemoglobinopathies and Related Disorders, Iron Metabolism and Disorders, Blood groups and transfusion, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
When cure exists but access does not.
Spirituality and cancer: quality of life, anxiety/depression and symptom severity.
From Science to Solidarity: A Two-Decade Collaboration in Thalassemia.
How I manage luspatercept in transfusion-dependent beta-thalassemia.
TIF Guidelines for the Management of Transfusion‐Dependent β‐Thalassemia
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial
Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat.
TIF Guidelines for the Management of Transfusion-Dependent β-Thalassemia.
Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder.
Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare?
Innovation Alone Is Not Enough: The Urgent Need for Equitable Access in Thalassemia Care.
Splenic Iron Overload Influence on Lumbar Spine BMD Reproducibility in β-Thalassemia.
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study.
Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words.
Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia
Αlpha-thalassemia: A practical overview
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial
von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease
Anemia and iron overload as prognostic markers of outcomes in β-thalassemia.
ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
Unmet needs in β-thalassemia and the evolving treatment landscape.
Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial.
COVID-19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet
Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps.
Thalassaemia—A global view
Cardiovascular Complications in β-Thalassemia: Getting to the Heart of It
Thalassaemia-A global view.
How I treat non-transfusion-dependent β-thalassemia.